What is it about?
This is a workshop summary in which we describe the best methods for assessing lung function in muscular dystrophy.
Featured Image
Why is it important?
This is a summary of the current state of the art about how lung function can be followed as an outcome measure in clinical trials of new therapies for muscular dystrophy.
Perspectives
This workshop was created to give guidance to researchers and to the FDA for how to judge new therapies for muscular dystrophy.
Dr. Jonathan Daniel Finder
University of Tennessee
Read the Original
This page is a summary of: Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary, American Review of Respiratory Disease, August 2017, American Thoracic Society,
DOI: 10.1164/rccm.201703-0507ws.
You can read the full text:
Contributors
The following have contributed to this page
